Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ivan Cichowicz

Geriatric Psychiatry Boca Raton, FL Medical Doctor

NPI 1932312840 CMS profile 589106

2201 Nw Corporate Blvd, Suite 202, Boca Raton, FL 33431

Open in the dashboard

General payments

$254,786

829 records reported · program years 2019–2025

Research payments

$1,499

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$527,051 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Ivan Cichowicz of Boca Raton, FL is reported in the CMS Open Payments database as having received $254,786 across 829 general payments and $1,499 in research payments paid to them. Separately, studies naming them as principal investigator received $527,051 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Geriatric Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $87,533 171
2024 General $32,767 124
2023 General $66,255 197
2022 General $21,309 81
2021 General $12,527 88
2020 General $10,926 70
2019 General $23,469 98
2019 Research $1,499 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivan Cichowicz
  • Geriatric Psychiatry median
  • Middle half of Geriatric Psychiatry
  • National median

In program year 2025, general payments to Ivan Cichowicz were reported at $87,533. Among 188 Geriatric Psychiatry profiles paid that year, the median was $125 and the middle half received between $52 and $515.

Show as a table
Year Ivan Cichowicz Geriatric Psychiatry median Middle half National median
2019 $23,469 $151 $47–$484 $163
2020 $10,926 $112 $30–$410 $114
2021 $12,527 $122 $35–$550 $132
2022 $21,309 $133 $54–$557 $149
2023 $66,255 $138 $61–$485 $160
2024 $32,767 $127 $51–$572 $164
2025 $87,533 $125 $52–$515 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $186,326 287 payments
  2. ITI, Inc. $52,445 102 payments
  3. LivaNova USA, Inc. $7,005 19 payments
  4. Otsuka America Pharmaceutical, Inc. $1,748 54 payments
  5. Teva Pharmaceuticals USA, Inc. $1,368 50 payments
  6. Lundbeck LLC $1,176 92 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $1,030 70 payments
  8. AbbVie, Inc. $812 49 payments
  9. Alkermes, Inc. $556 25 payments
  10. Axsome Therapeutics, Inc. $419 8 payments
  11. Other $1,902 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $201,735 86 payments
  2. Travel and Lodging $23,458 100 payments
  3. Food and Beverage $18,805 632 payments
  4. Consulting Fee $5,500 2 payments
  5. Honoraria $5,200 1 payment
  6. Education $87 8 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $186,326 287 payments
  2. CAPLYTA Psychiatry $50,983 65 payments
  3. VNS THERAPY SYMMETRY MODEL 8103 GENERATOR Neurology $6,290 11 payments
  4. REXULTI $1,610 52 payments
  5. CAPLYTA Psychiatry $1,462 37 payments
  6. TRINTELLIX $962 63 payments
  7. VRAYLAR $739 45 payments
  8. VNS Therapy Symmetry Model 8103 Generator Cardiology/Vascular Diseases $715 8 payments
  9. AUSTEDO $691 32 payments
  10. BRINTELLIX $674 66 payments
  11. Other $6,533 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,499 13 payments

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

4,803

Median for Psychiatry: 574

Drug cost

$764,845

Median for Psychiatry: $27,624

Branded share of claims

25%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 21 $153,090
Austedo Deutetrabenazine Brand 16 $112,105
Ingrezza Valbenazine Tosylate Brand 12 $102,089
Trintellix Vortioxetine Hydrobromide Brand 101 $83,433
Rexulti Brexpiprazole Brand 38 $70,983
Caplyta Lumateperone Tosylate Brand 41 $65,217
Lybalvi Olanzapine/Samidorphan Malate Brand 13 $19,545
Vraylar Cariprazine Hcl Brand 11 $17,115
Vilazodone Hcl Generic 177 $14,860
Auvelity Dextromethorphan Hbr/Bupropion Brand 15 $14,244

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$788,869

Medicare's payments for the services billed

Medicare patients

439

Average age 77

Services billed

5,225

286 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 66%
Ischemic heart disease 43%
Osteoporosis 35%
Diabetes 34%
Chronic kidney disease 32%
Alzheimer's or dementia 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
$24,136 — —
REXULTI
$708 38 —
CAPLYTA
$583 41 —
Auvelity
$263 15 —
Xelstrym
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

842 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record